viewFresenius Medical Care

Fresenius Medical Care acquires renal information software NephroCare


Fresenius Medical Care (NYSE: FMS) has completed the purchase of sole Canadian development and distribution rights to the NephroCare software from Cybernius Medical.

NephroCare is a comprehensive renal information system that electronically manages and reports patient data.
“The NephroCare(R) software allows easy access at the patient's bedside to enable point of care charting in the electronic patient record. It can also provide remote access to patient data for care givers and allow patients access to their own information through patient portal links,” Fresenius Medical Care stated.

Fresenius Medical Care has been distributing NephroCare in Canada for ten years.

Juan Sanchez, FMCC President stated: "Owning the NephroCare software clearly supports our vision to be first choice in renal therapies and reflects well on our on-going commitment to the Canadian renal eHealth market."

Fresenius Medical Care is an integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure.

Quick facts: Fresenius Medical Care

Price: 41.01 USD

Market: NYSE
Market Cap: $24.64 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Co-Diagnostics expects to win a CE mark-validated...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the Utah-based company expects to achieve a CE mark validation on its coronavirus detection test from the European Union by as early as next week. Egan says the company is very enthused by the entire process of the development...

1 day, 18 hours ago

2 min read